Integrated Diagnostics

NEW YORK (GenomeWeb) – Integrated Diagnostics said this week that it has obtained $47.25 million in funding, $30.25 million from the closing of its Series B round and $17 million in non-dilutive debt financing from Life Sciences Alternative Funding.

SISCAPA Assay Technologies has appoint Gustavo Salem president and CEO.
Salem was previously an SAT board member. Prior to that he was VP and general manager of the Biological Systems Division at Agilent as well as president and CEO of Assay Designs.

SAN DIEGO – The Mass Spectrometry Applications to the Clinical Laboratory annual meeting arrived this week in San Diego with mass spec-based clinical proteomics having made significant strides in the last year.

This story has been updated with comments from outside researchers and clinicians. LC-MS-based proteomics has officially entered the clinic with the launch this week of Integrated Diagnostics' Xpresys Lung test.

Integrated Diagnostics has published a study this week in Science Translational Medicine presenting the discovery and initial validation research underpinning its forthcoming proteomic lung can

Integrated Diagnostics said this week that it has spun out its protein catalyzed capture agent business into a new firm, InDi Molecular.

On a conference call last month following the release of its Q1 earnings, Vermillion CEO Thomas McLain announced that the company would be taking over from Quest Diagnostics as leader of commercialization efforts for its OVA1 ovarian cancer diagnostic (

In March 2010, Austin, Texas-based diagnostics firm Vermillion launched sales of its OVA1 ovarian cancer test.